Drug Approvals: An 18-Year High
Mar 27, 2015
Making full use of its "breakthrough therapy" accelerated review protocol the US Food and Drug Administration in 2014 approved 51 new therapies, the most in 18 years.
FDA Warns Against Amiodarone Use With Hepatitis C Meds
Mar 26, 2015
Symptomatic bradycardia can occur when amiodarone is taken with new hepatitis C medications, the U.S. Food and Drug Administration warns.
Future Treatment May Be Best for Kids with Hepatitis C
Mar 11, 2015
The best time to treat children infected with the hepatitis C virus may be off in the future when newer, better drugs with fewer side effects are expected to be approved for pediatric populations.
Study Looks at Philadelphia Community-Based Hepatitis C Screening Program
Mar 10, 2015
A Philadelphia program operating in underserved neighborhoods found that residents chronically infected with the hepatitis C virus often lacked access to screening as well as treatment for the disease.
Hepatitis C Virus Treatment on an Individual Basis
Mar 05, 2015
Physicians must decide on a case by case basis which patients will benefit the most from hepatitis C virus therapy, according to an editorial in JAMA Internal Medicine.
NS5A/ NS3 Combo Hepatitis C Treatment Delivers Excellent Sustained Virologic Response in Patients Coinfected with HIV
Mar 01, 2015
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
Combo Drug Shows High Hepatitis C Cure Rates in Patients Coinfected with HIV
Mar 01, 2015
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MJH Associates >
Specialty Pharmacy Times
Terms & Conditions
Copyright HCPLive 2006-2015 Intellisphere, LLC. All Rights Reserved.